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Precis 
This preliminary investigation of GATA3 staining of cell block specimens found high 
sensitivity (90%) and specificity for metastatic breast carcinoma. The sensitivity was superior 
to both mammaglobin and GCDFP-15. 
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Abstract 
Background: The utility of GATA3 as a marker for metastatic breast carcinoma in serous 
effusion specimens was investigated. 
Methods: Cell block sections from 74 serous effusion specimens (32 ascitic, 2 pericardial 
and 40 pleural fluids) were stained with an anti-GATA3 murine monoclonal antibody.  The 
specimens included 62 confirmed metastatic carcinomas from breast (30), female genital tract 
(13), gastrointestinal tract (7), lung adenocarcinoma (9), pancreas (1), kidney (1) and bladder 
(1).   The breast carcinoma cases included 15 ductal carcinomas, 8 lobular carcinomas and in 
7 the histology sub-type was not available. Twelve cases containing florid reactive 
mesothelial cells were also stained. The breast carcinoma cases were also stained for 
mammaglobin and GCDFP-15 to compare sensitivity with GATA3. 
Results: Positive nuclear staining for GATA3 was present in 90% (27/30) of metastatic 
breast carcinoma specimens. All non-breast metastatic carcinomas tested were negative with 
the exception of the single case of metastatic urothelial carcinoma. No staining was observed 
in any of the benign reactive cases or in benign mesothelial cells present in the malignant cell 
block preparations. Two cases showed weak positivity of benign lymphoid cells. Staining 
results were unambiguous as all positive cases showed intense nuclear staining in >50% of 
tumor cells. Mammaglobin (57%; 17/30) and GCDFP-15 (33%; 10/30) were less sensitive 
markers of breast carcinoma. If used in a panel, mammaglobin and GCFP-15 staining would 
have identified only one additional case to those stained with GATA3. 
Conclusions: GATA3 may be a useful addition to immunostaining panels for serous effusion 
specimens when metastatic breast carcinoma is a consideration. 
  
Page 2 of 20Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 
 
Keywords: 
GATA3; serous effusions; metastatic breast carcinoma; metastatic adenocarcinoma; 
immunohistochemistry 
 
Introduction 
Breast carcinoma is the most common metastatic malignancy identified in pleural effusion 
specimens from women and the second most frequent cause of ascites in females.
1-3
 The 
cytomorphology of breast carcinoma in effusions varies considerably and shows overlap with 
both reactive mesothelial cells and with metastases from other primary sites. A not 
uncommon problem is posed when metastatic breast carcinoma cells present in a 
predominantly dispersed pattern.
4
  The cells are often of similar size and shape to mesothelial 
cells with subtle nuclear changes and may be misinterpreted as reactive mesothelial cells. 
Furthermore up to 15% of malignant effusions develop in the absence of a documented 
primary tumor
3
 and identification of the primary site in this setting is useful in directing 
management. 
Immunohistochemistry (IHC) plays a valuable role in effusion cytology in the identification 
of metastatic malignancy, particularly in discriminating metastatic carcinoma from benign 
and malignant mesothelial cells. However, the reliable identification of breast as the primary 
site is more difficult. Several markers for breast carcinoma have been utilized, however those 
investigated to date lack either sensitivity or specificity.   
GATA3 (GATA binding protein 3 to DNA sequence [A/T]GATA[A/G]) is a member of the 
zinc finger transcription factor family. It is implicated in promoting cellular proliferation and 
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differentiation in many tissues and cell types
5,6
 and has recently  been reported to be a 
sensitive and specific marker for urothelial and breast carcinomas in tissue sections.
7
  
 
This study investigated the value of GATA3 in identifying metastatic breast carcinoma cells 
in effusion specimens and in discriminating them from mesothelial cells and from non-
mammary metastatic carcinoma. The sensitivity of GATA3 for metastatic breast carcinoma 
was also compared with that for two commonly used breast markers, GCDFP-15 and 
mammaglobin. 
Materials and Methods 
Specimens 
Seventy-four serous effusion specimens from 74 patients were included in the study, 
including 32 ascitic, 2 pericardial and 40 pleural fluids. The specimens included 62 metastatic 
carcinomas from breast (30), female genital tract (13), gastrointestinal tract (7), lung 
adenocarcinoma (9), pancreas (1), kidney (1) and bladder (1).  All malignant cases had 
previous histology confirming the primary site, a cytology report of carcinoma and, in most 
cases, other IHC staining results on the cell block consistent with the cytological diagnosis. 
The breast carcinoma cases included 15 ductal and 8 lobular carcinomas, and in 7 cases the 
histology report for the primary tumor was not available. Twelve cases containing florid 
reactive mesothelial cells, confirmed by IHC, were also stained for GATA3. 
Immunohistochemistry 
Cell blocks were prepared as previously described.
8
 All immunohistochemical stains were 
performed on an automated Ventana Benchmark Ultra instrument. Details of primary 
antibodies used in this study, together with pre-treatment conditions are shown in Table 1. 
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GATA3 staining utilized the OptiView (Ventana) detection system while the UltraView 
(Ventana) sytem was used for mammaglobin and GCDFP-15 staining. Stained sections were 
scored positive if >10% of cells showed nuclear staining (for GATA3) or cytoplasmic 
reactivity (for GCDFP-15 and mammaglobin) respectively. 
Results 
Positive nuclear staining for GATA3 was present in 90% (27/30) of breast carcinomas (Table 
1), including a majority of both known ductal and lobular carcinomas. Staining results were 
unambiguous as all positive cases showed strong nuclear staining in >50% of tumor cells. 
Strong nuclear staining served to highlight malignant cells in a number of cases with a 
difficult cytological presentation, including specimens with dispersed small malignant cells 
(Figure 1) and small malignant cells amongst numerous leucocytes (Figure 2). The single 
case of urothelial carcinoma was positive, however all other non-breast metastatic 
adenocarcinomas tested were negative. No staining was observed in any of the benign 
reactive cases or in benign mesothelial cells present in the malignant cell block preparations. 
Two cases showed weak nuclear positivity in benign lymphoid cells. 
Estrogen receptor (ER) status assessed on the primary tumor histology or cell block specimen 
was available for 25 metastatic breast carcinoma cases. GATA3 staining was positive in 
100% (21/21) ER positive cases and 75% (3/4) of ER negative cases. Three of the serous 
carcinomas were also ER positive but GATA3 negative. 
Mammaglobin and GCDFP-15 staining of the metastatic breast carcinoma cases was positive 
in 57% (17/30) and 33% (10/30) respectively. The addition of either of these markers to 
GATA3 resulted in only a minimal improvement in sensitivity. Of the three GATA3 negative 
cases, one was positive for mammaglobin and all were negative for GCDFP-15. 
Page 5 of 20 Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6 
 
Discussion 
The cytomorphology of metastatic breast carcinoma in serous effusion specimens is quite 
variable. Malignant cells may be arranged in cell groups, linear arrangements, large cell balls, 
predominantly isolated cells or a combination of these.
9
 Nuclear morphology also varies, with 
some cases showing clearly malignant features while others have subtle nuclear changes and 
hence may closely mimic reactive mesothelial cells.  Thus reliably identifying breast as the 
primary site or, in some cases, identifying the effusion as malignant based on morphology 
may be difficult. 
In most cases a history of primary breast carcinoma is known and reporting the 
cytomorphology as consistent with metastatic adenocarcinoma is sufficient. However in some 
cases immunophenotypic confirmation of a breast primary is helpful. This includes cases 
where no known primary diagnosis is available or, if present, was many years distant and 
cases in which a second malignancy may be present or suspected. A reliable marker for breast 
carcinoma would also be valuable in those cases with bland morphology where 
discrimination from reactive mesothelial cells is problematic. Several markers have been 
investigated to fill this role, however to date they lack sensitivity or specificity for metastatic 
breast carcinoma. 
Gross cystic disease protein (GCDFP-15) is a glycoprotein originally isolated from human 
gross cystic disease fluid that has been used as a marker for breast carcinoma. 
Immunohistochemical studies of tissue specimens have reported expression of GCDFP-15 in 
41-73% of breast carcinomas, as well as some sweat gland, salivary gland tumors and a small 
proportion of lung adenocarcinomas.
10,11,12
   When applied to effusion specimens, GCDFP-15 
has shown poor sensitivity. Yan et al
13
 reported 47% (7/15) of metastatic breast carcinomas 
to be positive, while Lee et al
14
 found only 14% (4/29) positive. A study of 23 primary and 
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metastatic mammary carcinomas and 20 non-mammary tumors in fine needle aspiration and 
body fluid specimens reported 100% specificity but only 56% sensitivity.
15
  
Mammaglobin has also been utilized as a breast marker.  It is a secretory glycoprotein with 
homology to other secretoglobin-uteroglobin family members. It has been reported to be 
expressed in 48-72% of breast carcinomas, 11-39% of endometrial carcinomas, 40% of sweat 
gland carcinomas, 20% of salivary gland tumors and in rare lung adenocarcinomas.
11,12,16,17
 A 
comparison of immunohistochemical staining of whole tissue sections and tissue microarrays 
with GCDFP-15 and mammaglobin found the latter to be more sensitive (55% Vs 23% 
positive) but less specific than GCDFP-15, staining 8% of non-breast tumors, particularly 
endometrioid carcinomas.
11
  Two small studies have examined the value of mammaglobin as 
a marker for breast carcinoma in body fluids. These reported a sensitivity of 55% (11/20)
18
 
and 87% (13/15)
13
 for breast carcinoma. Both studies found high specificity for 
mammaglobin, although the number of non-mammary carcinomas examined was small. Yan 
et al
13
 reported 3/25 non-mammary carcinomas, including two ovarian and one colonic, to be 
positive.  
Estrogen receptor (ER) and progesterone receptor (PR) have also been applied to identify 
breast carcinoma in effusion specimens but, although mesothelial cells are negative, both 
receptors are commonly expressed in gynecological malignancies
14
, and pulmonary 
adenocarcinomas infrequently express ER.
12,19
 
Recent IHC studies suggest that GATA3 may be a more effective marker.
7,20
 Lui et al
7
 
assessed GATA3 expression in 1110 carcinomas and 310 normal tissue samples in tissue 
microarrays as well as 48 biopsy specimens. Positive staining was found in 94% (138/147) of 
breast carcinomas and 86% of urothelial carcinomas. Other non-mammary tumors were 
negative except for rare endometrial carcinomas (2/96). GATA3 expression has also been 
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reported in normal and neoplastic parathyroid cells, in T-cells and in both Hodgkin and non-
Hodgkin lymphomas. A number of studies have confirmed that amongst epithelial tumors, 
GATA3 has relatively high sensitivity and specificity for urothelial and breast carcinoma, 
including expression in all histological sub-types of breast carcinoma.
20
 Lui et al
7
 also 
evaluated GATA3 staining of cell block preparations from 53 fine needle aspiration 
specimens (FNA) and reported 88% of 17 primary and 82% of 22 metastatic breast 
carcinomas to be positive. Fourteen FNA samples from benign breast lesions were all 
negative.  
Results from the current study indicate that GATA3 is a promising marker for metastatic 
carcinoma when applied to cell block preparations of serous effusion specimens. The 
sensitivity of GATA3 staining in this study was 90%, with staining observed in a high 
proportion of both ductal and lobular carcinomas. This was superior to that observed with 
mammaglobin (57%) and GCDFP-15 (33%).  The latter was also quite focal in most cases, in 
contrast to GATA3 staining which labelled the majority of tumor cells in all cases tested.  
Based on the limited sample of breast carcinomas investigated, the use of either of these 
markers in addition to GATA3 would result in minimal improvement in sensitivity, and, 
based on results of other studies, may reduce the specificity for breast carcinoma. 
In some studies GATA3 expression has been found to correlate with tumor grade
7
 and with 
ER and PR status,
21
 however other investigators have reported GATA3 expression in triple 
negative poorly differentiated breast carcinomas.
22
 Although our data were incomplete with 
regard to ER status, we also found GATA3 expression in ER negative cases. All 21 ER 
positive cases and 3/4 ER negative cases were GATA3 positive. The three known triple 
negative cases in the current study were all positive for GATA3.  A recent tissue-based study 
examining 30 paired primary and metastatic breast carcinomas found GATA3 expression in 
90% of tumors, including 67% of triple negative cases.
22
 GATA3 expression was maintained 
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in metastases, including so-called ‘luminal loss’ metastases that showed ER and/or PR loss, 
suggesting GATA3 may be a useful marker for these poorly differentiated breast carcinomas. 
 
GATA3 staining also showed high specificity in the current study. In all of the non-mammary 
adenocarcinoma cases a negative reaction was noted, including nine metastases from lung 
and 13 gynecologic carcinomas, the most common differential diagnoses with breast 
carcinoma in a malignant effusion of unknown cause in females. The single case of urothelial 
carcinoma (UC) metastatic to pleura was positive, however this tumor is rarely seen in 
effusion specimens, even more rarely without a known primary site. The case included in this 
study presented with a known history of UC and was negative for CK5, calretinin, EMA, 
Ber-EP4 and was CK 7 and CK 20 positive.  Nevertheless, in the appropriate setting, it is 
important to remember that GATA3 is expressed by a high proportion of urothelial 
carcinomas.   
In conclusion, this initial study indicates that GATA3 may be a useful addition to IHC panels 
for effusion cytology when metastatic breast carcinoma is a consideration. 
 
  
Page 9 of 20 Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
References 
1. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnosis 
of 564 specimens from 472 consecutive patients. Cancer 1985;56:905-909. 
2. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5,255 
samples from 3,811 patients. Diagn Cytopathol 1987;3:8-12. 
3. Sears D, Hadju SI. The cytologic diagnosis of malignant neoplasms in pleural and 
peritoneal effusions. Acta Cytol 1987;31:85-97. 
4. DeMay RM. The Art and Science of Cytology. 2
nd
 Ed. Chicago: ASCP Press. 2012. 
5.  Burch JB. Regulation of GATA gene expression during vertebrate development. 
Semin Cell Dev Biol 2005;16:71-81. 
6. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer 
2010;1:1178-1188. 
7. Liu H, Shi J, Wilkerson M, Lin F. Immunohistochemical evaluation of GATA3 in 
tumors and normal tissues.  A useful immunomarker for breast and urothelial 
carcinomas. Am J Clin Pathol 2012;138:57-64.  
8. Shield PW, Duricic D, Truong TT. Evaluation of an agar cell block method to 
improve cell yield in non-gynaecological cytology specimens. Aust J Med Sci 
2013;34:20-23. 
9. Periera TC, Saad RS, Liu Y, Silverman J. The diagnosis of malignancy in effusion 
cytology: a pattern recognition approach. Adv Anat Pathol 2006;13:174-184. 
10. Wick MR, Lillemore TJ, Copland GT et al. Gross cystic disease protein-15 as a 
marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and 
comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-287. 
Page 10 of 20Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11 
 
11. Bhargava R, Breriwal S, Dabbs DJ.  Mammaglobin Vs GCDFP-15: an 
immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 
2007;127:103-113. 
12. Yang M, Nonaka D. A study of immunohistochemical differential expression in 
pulmonary and mammary carcinomas. Mod Pathol 2010;23:654-661. 
13. Yan Z, Gidley J, Horton D et al. Diagnostic utility of mammaglobin and GCDFP-15 
in the identification of metastatic breast carcinoma in fluid specimens. Diagn 
Cytopathol 2009;37:475-478.  
14. Lee BH, Hecht JL, Pinkus JL, Pinkus JS. WT1, Estrogen receptor and progesterone 
receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma 
to body fluids Am J Clin Pathol 2002;117:745-750. 
15. Fiel MI, Cemaianu G, Burstein DE, Batheja N. Value of GCDFP-15 (BRST-2) as a 
specific immunocytochemical marker for breast carcinoma in cytologic specimens. 
Acta Cytol1996;40:637-641. 
16. Sasaki E, Tsunoda N, Hatanaka Y et al. Breast-specific expression of 
MGB1/mammaglobin: an examination of 480 tumors from various organs and 
clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 
2007;20:208-214. 
17. Wang Z, Spaulding B, Sienko A, et al. Mammaglobin, a valuable diagnostic marker 
for metastatic breast carcinoma. Int J Clin Exp Pathol 2009;2:384-389. 
18. Ciampa A, Fanger G, Khan A, Rock KL, Xu B. Mammaglobin and CRxA-01 in 
pleural effusion cytology. Potential utility of distinguishing metastatic breast 
carcinoma from other cytokeratin7-positive/cytokeratin 20-negative carcinomas. 
Cancer (Cancer Cytopathol) 2004;102:368-372. 
Page 11 of 20 Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12 
 
19. Dabbs DJ, Landreneau RJ, Liu Y et al. Detection of estrogen receptor by 
immunohistochemistry in pulmonary adenocarcinomas. Ann Thorac Surg 
2002;73:403-405. 
20. Ordonez NG. Value of GATA3 immunostaining in tumor diagnosis: A review. Adv 
Anat Pathol 2013;20:352-360. 
21. Hoch RV, Thompson DA, Baker RJ, et al. GATA3 is expressed in association with 
estrogen receptor in breast cancer. Int J Cancer 1999;84:122-128. 
22. Cimino-Matthews A, Subhawong A, Illei PB et al. GATA3 expression in breast 
carcinoma: utility in triple negative, sarcomatoid, and metastatic carcinomas. Hum 
Pathol 2013;44:1341-1349. 
  
Page 12 of 20Cancer Cytopathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13 
 
 
 
Figure 1. Metastatic breast ductal carcinoma cells in a pleural fluid.  (a): Quick Dip stain (x20 
obj); (b): Papanicolaou stain; (x40 obj) (c): GATA3 stain (x40 obj).  
 
 
 
 
Figure 2. Metastatic  breast lobular carcinoma cells in a pleural fluid. Linear arrangements of 
small malignant cells in a background of mesothelial cells and numerous leucocytes. (a): 
Quick Dip stain; (b): Papanicolaou stain; (c): GATA3 stain. (All x40 obj.) 
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Table 1. Details of the antibodies used in immuohistochemical staining of cell block 
specimens. (M) Mouse monoclonal antibody. 
Antigen Clone Supplier Dilution Pretreatment 
CC1 (min) 
Time 
(min) 
GATA3 L50-823 
(M) 
BD Pharmingen, Franklin 
Lakes, NJ 
1:7500 32 32 
GCDPF-15 23A3 (M) Novocastra, Leica 
Microsystems, Sydney, 
Australia 
Pre-
dilute 
36 20 
Mammaglobin 304-1A5 
& 31A5 
(M) 
Cell Marque, Rocklin, CA 1:125 20 32 
 
 
Table 2. GATA3 staining results on malignant cell block specimens by primary tumor site 
and histological type. 
Primary site/ type GATA3 
Pos/Total  
   Ductal breast 14/15 
   Lobular breast 8/8 
   Not known 4/7 
Total Breast  27/30 (90%) 
   Ovarian serous carcinoma 0/10 
   Ovarian  clear cell 0/1 
   Fallopian tube serous carcinoma 0/1 
   Endometrial endometriod 0/1 
Female genital tract total 0/13 (0%) 
   Colon 0/2 
   Stomach 0/3 
   Gall bladder 0/2 
Gastrointestinal tract total 0/7 (0%) 
Lung adenocarcinoma 0/9 (0%) 
Pancreas 0/1 (0%) 
Kidney clear cell 0/1 
Total Non-breast adenocarcinoma 0/31 (0%) 
 
Bladder Urothelial carcinoma 1/1 (100%) 
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